Stereotaxis (STXS) Cash from Financing Activities (2010 - 2026)
Stereotaxis' (STXS) quarterly Cash from Financing Activities came in at $4.7 million in Q1 2026, up 14637.5% year-on-year from N/an in Q1 2025, and down 32.18% on a QoQ basis from $7.0 million in Q4 2025.
Stereotaxis (STXS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has 17 years of Cash from Financing Activities data on file, last reported at $4.7 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 14637.5% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $19.4 million, a 6404.01% increase from a year earlier, with the FY2025 full-year figure at $14.8 million, up 4870.71% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $4.7 million, down from $7.0 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for STXS reached as high as $7.7 million in Q3 2025 and fell as low as -$26000.0 in Q2 2023.
- Historically, Cash from Financing Activities has averaged $1.2 million across 5 years, with a median of $54000.0 in 2022.
- Across the five-year window, Cash from Financing Activities plunged 145.61% in 2023 and soared 14637.5% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $61000.0 in 2022, then plunged by 57.38% to $26000.0 in 2023, then soared by 511.54% to $159000.0 in 2024, then jumped by 4273.58% to $7.0 million in 2025, then plunged by 32.18% to $4.7 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $4.7 million in Q1 2026, $7.0 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -133.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -414.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -13.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -255.24 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -50.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -48.13 Mn |
| 10 | Stereotaxis | 136.49 Mn | 121.87 Mn | 3.79 Mn | 4.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.72 Mn |
| Mar 31, 2026 | 4.72 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |